23 Nov 2012 07:00
Press Release | 23 November 2012 |
LIDCO GROUP PLC
("LiDCO" or the "Company")
LiDCOrapid v2 with Unity software satisfies NICE recommendations for the use of depth of anesthesia monitors and fluid monitoring during high risk surgery
LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, welcomes new guidance from the National Institute for Health and Clinical Excellence ("NICE") recommending the use of depth of anaesthesia ("DOA") monitors during general surgery in higher risk patients. Use of Covidien's Bispectral Index ("BIS™") DOA technology, accessible through the new LiDCOrapid v2 monitor, was highlighted in the NICE report as showing the strongest evidence of clinical benefit.
This new recommendation suggests that use of DOA monitoring is adopted for all high-risk surgery patients undergoing general anaesthesia. In the UK at least 340,000 high risk patients are operated on under general anesthetic each year and could benefit from this type of monitoring.
This recommendation builds on previous guidance from NICE and the Commissioning for Quality and Innovation ("CQUIN") payment framework, both of which support intraoperative fluid management monitoring for high risk surgery patients. The LiDCOrapid v2 provides such fluid monitoring parameters and now co-displays Covidien's BIS™ DOA parameter. This new monitor also adds the convenience of CNSystem's continuous non-invasive blood pressure monitoring. The LiDCOrapid v2 with Unity software is a single monitor solution design that satisfies both NICE recommendations and CQUIN requirements in high risk surgery patients. Combining these features into a single monitor makes use of the LiDCOrapid v2 highly appealing compared to older, single parameter technologies.
Dr Terry O'Brien, CEO of LiDCO, commented: "The NHS is prioritizing fluid management to improve patient outcomes. From April 2013, fluid monitoring in high risk surgery patients will be a pre-qualifier for receiving payments under the CQUIN framework. This review confirms that inadequate or excessively deep levels of anaesthesia can be traumatic for high risk surgery patients; complications include post-traumatic stress disorder, cognitive dysfunction and increased incidence of stroke and heart attack. Depth of anaesthesia monitoring clearly can benefit high risk surgery patients.
Our product development has successfully anticipated NICE recommendations for excellence in high risk surgical patient care. The LiDCOrapid v2 is the first monitor to be designed specifically for multi-parameter monitoring of both depth of anesthesia and fluids, making our technology an excellent proposition when hospital are considering how to best use scarce hospital resources.
The new LIDCOrapid v2 monitor will be available shortly and our existing monitor installed base can be easily upgraded to ensure that all hospitals could benefit from LiDCO's parameter integration and respond to this latest NICE recommendation."
Reference:
Depth of anaesthesia monitors - Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (NICE, November 2012)
- Ends -
For further information, please contact:
LiDCO Group Plc | |
Terry O'Brien (CEO) | Tel: +44 (0)20 7749 1500 |
Paul Clifford (Finance Director) | |
John Rowland (Company Secretary) | www.lidco.com |
finnCap | |
Geoff Nash / Henrik Persson Stephen Norcross (broking) | Tel: +44 (0)20 7600 1658 www.finncap.com |
Media enquiries:
Abchurch | |
Adam Michael / Joanne Shears / Simone Elviss Jamie Hooper | Tel: +44 (0) 20 7398 7728 |
simone.elviss@abchurch-group.com | www.abchurch-group.com |
About LiDCO Group Plc
LiDCO is a supplier of minimally invasive hemodynamic equipment to hospitals, to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimization protocols for high risk patients in both critical care units and in the operating theatre.
Increasingly clinical studies are showing that the optimization of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.
Key Products:
LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%) | |
LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anesthetists to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides: | |
·; | early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug |
·; | quantification of hemodynamic response, |
·; | guidance on effective delivery of fluids to ensure the right amount at the right time |
LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data. | |
LiDCO Unity Software: The software incorporated into LiDCOrapid v2 will allow the LiDCOrapid monitor to co-display Covidien's level of consciousness parameter and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring. This will address a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors. | |
All LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.
LiDCO Distribution Network:
LiDCO's strategy is to sell directly to hospitals in the UK, and through a network of specialty critical care and anesthesia distributors in the rest of the world.
LiDCO's sales office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM. For more information please see www.lidco.com.